Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Antiviral Activity of VIR-3434 in Healthy Volunteers and Chronic Hepatitis B
NCT04423393Phase 1Completed
- Sponsor
- Vir Biotechnology
- Start
- May 2020
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing VIR-3434 with Placebo (2 arms). Primary endpoints: Number of Participants With Treatment-emergent Adverse Events at 8 weeks and Number of Participants With Clinical Laboratory Abnormalities at 280 days. Started May 2020; status: completed.
02
Drugs
tobevibart
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04423393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04423393.